STORY
/ Business
MONSANTO BAYER ARE MANEUVERING TO TAKE OVER THE CANNABIS INDUSTRY
BHSYNERGY | FEBRUARY 06, 2021 |
0
story image
It has been rumored for years that Monsanto plans to take over the cannabis industry with genetic engineering just as they’ve taken over the corn and soy industries. Although they have always denied having any intentions to do so, at this point it is unlikely that anybody really believes them. In contrast, many in the cannabis sphere are prepared to resist any kind of GMO takeover of marijuana by Monsanto or any of their cohorts.

Evidence is mounting, though, which points strongly to the notion that Monsanto does indeed plan to take control of the cannabis plant, and it doesn’t look good for medical users, or anyone planning on getting into the industry.

Former Nazi Collaborator Bayer Buys Out Monsanto for $66 Billion

You may remember hearing back in September that Bayer, the largest pharmaceutical company in the world, made a deal to buy out Monsanto for $66 billion. Although Monsanto was voted the most evil company in the world in 2013 and its reputation has continued to fall since, Bayer still went ahead with the buyout.

A merger between these two companies is unsurprising, as though they both have long histories of involvement with Nazism and chemical weapons like agent orange which have devastated Vietnam since the war. In fact, Bayer began as a break-off company of the infamous IG Farben, which produced the chemical weapons used on the Jews during the Nazi reign. After the war, Farben was forced to break up into several companies, including BASF, Hoeschst, and Bayer.

Soon after at the Nuremberg trials, 24 Farben executives were sent to prison for crimes against humanity. However, in a matter of just 7 years each of them was released and began filling high positions in each of the former Farben companies, and many of them began working for the Russian, British, and American governments through a joint intelligence venture called “Operation Paperclip”.

“IG (Interessengemeinschaft) stands for “Association of Common Interests”: The IG Farben cartel included BASF, Bayer, Hoechst, and other German chemical and pharmaceutical companies. As documents show, IG Farben was intimately involved with the human experimental atrocities committed by Mengele at Auschwitz. A German watchdog organization, the GBG Network, maintains copious documents and tracks Bayer Pharmaceutical activities.” – Alliance for Human Research Protection

After all these years, Bayer is now richer and more powerful than their predecessor company I.G. Farben ever was.

Monsanto And Miracle-Gro Have Intimate Business Ties

According to Big Buds Magazine, Monsanto and Scotts Miracle-Gro have a “deep business partnership” and plan on taking over the cannabis industry. Hawthorne, a front group for Scotts, has already purchased three of the major cannabis growing companies: General Hydroponics, Botanicare, and Gavita. Many other hydroponics companies have also reported attempted buyouts by Hawthorne.

“They want to bypass hydroponics retail stores…When we said we won’t get in bed with them they said, ‘Well, we could just buy your whole company like we did with Gavita and do whatever we want.’” – Hydroponics Lighting Representative

Jim Hagedorn, CEO of Scotts Miracle-Gro, has even said that he plans to “invest, like, half a billion in [taking over] the pot business… It is the biggest thing I’ve ever seen in lawn and garden.”

He has also invested in companies such as Leaf, which grows cannabis in an electronically regulated indoor terrarium accessible via smartphone.

Bayer and Monsanto Trade Industry Secrets On Producing GMO Marijuana

It is logical that Bayer, being the parent company, would work together with Monsanto in order to share secrets which would advance mutual business. Many people in the cannabis industry have been warning about this, including Michael Straumietis, founder and owner of Advanced Nutrients.

“Monsanto and Bayer share information about genetically modifying crops,” Straumietis notes. “Bayer partners with GW Pharmaceuticals, which grows its own proprietary marijuana genetics. It’s logical to conclude that Monsanto and Bayer want to create GMO marijuana.” – Michael Straumietis

Conclusion

It is possible that Bayer and Monsanto could create a monopoly on marijuana seeds in the same way that they have created a monopoly on corn and soy. Through immense corporate power and the enforcement of international patent law, these corporations could place themselves in a position of total control over cannabis as a medicine as well as for recreational use by using the same model as they do with the food crops they control.

But not all hope is lost. There is still a chance to fight back against the Bayer-Monsanto monopoly by boycotting genetically engineered products, Miracle-Gro and other Scotts brand products, Bayer pharmaceuticals, and companies that do business with any of these. If you buy cannabis seeds, they can be stored for years to be used at a later date or if you live in an area where it is legal, grow your own, while supporting hydroponics and nutrient companies that don’t do business with these corporate behemoths.

“Corporations and people with hundreds of billions of dollars know marijuana is a miracle plant. They want to come in and steal our plants, seeds, and industry from us, we must stop them.” – Straumietis



Sources

BHSynergy. “Monsanto & Bayer Are Maneuvering To Take Over The Cannabis Industry.” Monsanto & Bayer Are Maneuvering To Take Over The Cannabis Industry - BH Synergy Group, 12 Feb. 2019, bhsynergygroup.com/monsanto-bayer-are-maneuvering-to-take-over-the-cannabis-industry/.

COMMENTS (0)

Pfizer Bets On Medical Cannabis With $6.7 Billion Acquisition
Dario SabaghiContributor
I cover the cannabis industry with a focus on Europe.
Follow
0
Dec 20, 2021,08:33am EST
Exterior view of Pfizer Pharmaceutical company's offices in Brussels, Belgium
Brussels, Belgium. 21st December 2020. Exterior view of Pfizer Pharmaceutical company's offices.GETTY
Pfizer is to enter the medical cannabis industry betting on a promising cannabinoid-based bowel disease treatment.

Last week, American multinational pharmaceutical and biotechnology corporation Pfizer signed an agreement with the clinical-stage company Arena Pharmaceuticals for a total equity value of around $6.7 billion.

Under the agreement terms, Pfizer acquires all shares for $100 per share in an all-cash transaction. Moreover, the press release reads that the proposed transaction will be subject to customary closing conditions, including receipt of regulatory approvals and approval by Arena's stockholders.

Arena Pharmaceuticals is a biotech company with one pipeline dedicated to cannabinoid-type therapeutics. The core of its cannabis operation consists of Olorinab (APD371), an investigational, oral, full agonist of the cannabinoid type 2 receptor (CB2), which aims to treat patients with diseases affecting the stomach and intestine. As Arena's website states, Olorinab is an investigational drug and is not currently approved for use by any health authority.

Arena's team is developing this cannabinoid-based drug with an initial focus on visceral pain associated with gastrointestinal disorders. Arena's website reads that this compound, through its selectivity for CB2 versus CB1, is under investigation for pain relief without psychoactive adverse effects.

CB1 and CB2 receptors bind to the endocannabinoid system, a complex cell-signaling system. These receptors are present throughout the human body. Endocannabinoids, such as THC and CBD, can bind to both receptors to signal that the endocannabinoid system needs to take action. However, the effects depend on the endocannabinoid receptor and the cannabinoid's interaction with the receptor.

MORE FROMFORBES ADVISOR
Best Travel Insurance Companies
ByAmy DaniseEditor
Best Covid-19 Travel Insurance Plans
ByAmy DaniseEditor
"The proposed acquisition of Arena complements our capabilities and expertise in Inflammation and Immunology, a Pfizer innovation engine developing potential therapies for patients with debilitating immuno-inflammatory diseases with a need for more effective treatment options," said in the press release Mike Gladstone, Global President of Inflammation & Immunology at Pfizer.

Amit D. Munshi, President and Chief Executive Officer (CEO) of Arena, said that Pfizer's capabilities would accelerate Arena's mission to deliver essential medicines to patients and believes this transaction represents the best next step for both patients and shareholders.

"We're delighted to announce Pfizer's proposed acquisition of Arena, recognizing Arena's potentially best in class S1P molecule and our contribution to addressing unmet needs in immune-mediated inflammatory diseases," he said.

Arena's portfolio also includes other non-cannabinoid drug pipelines, focusing on developing innovative potential therapies to treat several immuno-inflammatory diseases.

By acquiring Arena, Pfizer enters the medical cannabis industry and joins other Big Pharma companies in the cannabis space.

Big pharmaceutical companies have entered the market through several operations in the past years.

Canadian research and development (R&D) company Avicanna became a resident company at Jonhson & Johnson's JLabs in Toronto in 2017.

One year later, Canadian Tilray went global through an agreement with Swiss pharmaceutical company Novartis AG to develop and distribute its medical cannabis products in legal jurisdictions worldwide.

In May 2021, global biopharmaceutical company Jazz Pharmaceutical completed the acquisition of GW Pharmaceuticals, the developer of Epidiolex, the first FDA-authorized CBD medicine for treating children with Lennox-Gastaut and Dravet syndromes.

Like Big Tobacco companies, Big Pharma's interest in the medical cannabis industry grows with the space's fast-evolving cannabinoids industry. R&D on cannabinoids is achieving exciting results in the treatment application. For this reason, it is expected to see further involvement of pharmaceutical companies in the medical cannabis industry in the following years.

Follow me on Twitter or LinkedIn. Check out my website.
Dario Sabaghi
Dario Sabaghi
Follow
I am a freelance journalist interested in international news and the cannabis industry. I write about a wide range of... Read More

Editorial Standards
Print
Reprints & Permissions
Play Video

Join Our Conversation
One Community. Many Voices. Create a free account to share your thoughts. Read our community guidelines here
Oops, something went wrong
We detected some connectivity issues therefore we’re unable to load the Conversation

https://tekniikanmaailma.fi/lehmille...box=1670842283

ISTOCKPHOTO
TEKSTI JANI KAARO
Jaa Facebookissa
Jaa Twitterissä
Jaa sähköpostilla
Tuore tutkimus mutkistaa toiveita, että hyötykasvina käytettävää kuitu- ja öljyhamppua voitaisiin käyttää lehmien rehuna. Saksalaistutkimuksessa hamppua syöneet lehmät tulivat pilveen ja kannabiksen päihdyttävää yhdistettä eli tetrahydrokannabinolia (thc) päätyi maitoon yllättävän runsaasti.

Tutkimus sai inspiraationsa hyötykäyttöhamppujen kasvatuksen suosiosta Euroopan Unionin alueella. Sekä kuitu- että öljyhamppua – joissa on vain hyvin matalia pitoisuuksia päihdyttävää thc:tä – kasvatetaan yhä enemmän, ja sen sivuseurauksena myös hamppujätettä syntyy yhä enemmän. Hamppujäte olisi lehmille erittäin ravitsevaa ruokaa, mutta tähän asti ei ole tutkittu, päätyykö hyötykäyttöhampusta päihdyttäviä aineita maitoon.

TUTKIMUKSEN ENSIMMÄISESSÄ osassa lehmät saivat koko kasvista tuotettua rehua 920 grammaa, mutta tällä ei ollut mainittavaa vaikutusta lehmien käyttäytymiseen tai maidon thc-pitoisuuteen. Tämän jälkeen lehmille annettiin 840–1 680 grammaa fermentoitua rehua, jossa oli mukana kasvin lehtiä, nuppuja ja kukkia. Rehun kannabinoidipitoisuus oli selvästi hyötykasvihampulle asetettujen rajojen alapuolella, mutta sillä oli silti merkittäviä vaikutuksia lehmiin.

Ensinnäkin lehmät vähensivät syömistään ja maidontuotanto väheni. Niiden hengitystaajuus ja sydämen syke laski. Lisäksi ne vaikuttivat uneliailta, kuolasivat enemmän, leikkivät kielellään ja niiden silmät punertuivat. Lisäksi maidosta mitattiin niin korkeita thc-pitoisuuksia, että osa ylitti kuluttajille asetetut raja-arvot. Tutkijoiden mukaan mitatuilla thc-pitoisuuksilla voisi olla päihdyttäviä vaikutuksia esimerkiksi lapsilla.

MAINOS

×
PÄIHDYTTÄVÄÄ AINETTA sisältävän rehun syöttäminen ruokaa tuottaville eläimille ei ole ongelmatonta, tutkijat tiivistävät tuloksensa.

Tulokset ovat pettymys hyötykasvihampun kasvattajille, jotka joutuvat heittämään rehuksi kelpaavaa hamppujätettä kompostiin.

Jaa Facebookissa
Jaa Twitterissä
Jaa sähköpostilla
LISÄÄ AIHEESTA
Maanviljely Kannabis
Keskustelu
1 kommentti
R69415:53

Aarnion Jari voisi konsultoida tätä paremmin?

Kuullostaa omituiselta

Todella omituiselta

miten niin? Ihan selkotekstiä.

Joo tuo kuulosti oudolta. Mutta noiden tarkennuksien kanssa sulta ja G juttu avautu paremmin. Ja nyt sen tajuaa.

Siis.. hamppu jossa ei ollut mainittavasti thc:tä.. aiheutti sen, että lehmät päihtyivät ja maidossa oli thc:tä? Mistä se sinne päätyi jos sitä ei ollut siinä hampussa? Vai mitä en nyt ymmärrä?

ei ollut mainittavasti eli vähän..

( ) kaikessa hampussa on kannabinoideja. Teollisuushampussa ei ole mitenkään merkittäviä määriä, mutta kun rehu fermentoidaan niin kannabinoidit muuntuvat psykoaktiiviseen muotoon, jolloin suuri määrä rehua päihdyttää eläimen.

Jos ihminen syö 840–1 680 grammaa fermentoitua rehua, jonka kannabinoidipitoisuus on matala, niin taatusti lähes jokainen menee siitä tolkuttomaan, useita päiviä kestävään, pilveen.
Fermentaatioprosessin aikana kannabinoidit aktivoituvat. Jos ajatellaan, että rehun THC-pitoisuus olisi 1% niin tämähän vastaa 84-168 grammaa 10% kukintoa ja 42-84 grammaa 20% kukintoa. Täysikasvuinen lehmä painaa 700-1100kg, eli lehmän massan voidaan ajatella vastaavan 10-12 keskikokoista naista tai 10-12 isoa miestä. Jos suhteutetaan syöty kannabinoidimäärä massaan niin syöty määrä vastaisi ihmisellä vähimmillään 3,5 gramman kerta-annosta 20% kukinnolla ja suurimmillaan yli kahdeksaa grammaa 20% kukintoa.
Toki lehmän aineenvaihdunta, elimistö ja kannabinoidireseptorit poikkeavat ihmisestä, mutta en ihmettele lainkaan miksi fermentoitu rehu aiheutti lehmille päihtymystilan jos otetaan huomioon syödyn massan kokonaiskannabinoidimäärä.


"Täysikasvuinen lehmä painaa 700-1100kg, eli lehmän massan voidaan ajatella vastaavan 10-12 keskikokoista naista tai 10-12 isoa miestä."
-Toivo henkesi edestä ettei toi kuljeudu mihinkään 4th wave tosi"feminismi" ryhmään.. ����


tarkemmin luettuna väärinymmärryksen riski on ilmeinen.

Miten tuo voi olla mahdollista? Toisaalta lehmällä on erilainen elimistö. Mutta silti raakatavara. Hmm täytyy testata ja napsia raakaa kukkaa ihan testiksi. Lehtiä kyllä syön vakinaisesti salaattina. Mutta niistä ei ole muuta huomattavaa kuin jännä maku. Päihdytä se ei, mutta vatsa toimii hyvin.

salaattia

se pitää fermetoida eli käyttää jotta aktivoituu niin kuin tässä.


Aa tuo fermetointi on itselle aika vieras aihe alue. Pitänyt kokeilla sitä jo vuosia. No mutta tuopas olikin mainio tieto. Täytyy syventyä tohon aihealueeseen.


”Mitä jos meidänkin (joku henkilö) on tietämättään kannabismaitoa kaakaomukissaan pakkassäiltä lämmittämässä”


"lehmät vähensivät syömistään" niinhän siinä juu tuppaa käymään


asiavirheitä ja todellisuudenvastainen sisältö. maidon aminohappokoostumus parani ja eläimet olivat tyytyväisempiä, varmaankin riippuvat tulokset lajikkeestakin. eläinkokeet on jo tehty niinsanotulla yleislajikkeella ja tuloksien mainintahan ei vaikuta edes sallitulta. hamppu-kannabisasiathan saa käänneltyä vaikka miten päin, lehdistön motiivit kiinnostavia

Raportoi
Vastaa
Kirjaudu sisään kommentoidaksesi